Demonstrating the Value of Efficient PAT, AI & Machine Learning in Drug & Biologics Development & Manufacturing to Ensure Product Consistency
The Industry-Specific Event for PAT Experts in Pharma & Biopharma
Adopting Scalable & Cost-Efficient PAT Solutions for Drug & Biologics Manufacturing
As demand surges for GLP-1s, small molecules, and complex biologics, the industry faces increasing pressure to innovate and optimize manufacturing processes to meet the needs of Pharma 4.0. The 4th PAT & Real Time Quality Summit offers a unique opportunity to explore how PAT is transforming drug development and manufacturing, ensuring product consistency and reducing waste.
Across three days, 18+ industry leaders will share case studies, discuss the latest analytical tools, and demonstrate how digital technologies can be applied throughout the biologics and drug product lifecycle to save time and money. Attendees will dive into key topics, including regulatory updates, real-time release testing, and tech transfer challenges, while exploring the application of PAT for various drug modalities, including CGT, vaccines, peptides, and small molecules.
With experts from top pharma companies such as AstraZeneca, GlaxoSmithKline, and Pfizer, this Summit provides an unmatched platform to discuss strategies for improving processes and accelerating the adoption of scalable, cost-effective PAT solutions. Don't miss the chance to connect with other PAT practitioners and gain the insights needed to navigate the future of pharma manufacturing.
Full Event Guide
World-Class Speaker Faculty Includes:
Preeya Boppana
Director, Manufacturing Science & Technology, Process Analytics & Laboratories
AstraZeneca
Previously Attending Companies Include:
What Made Us Different?
"Was great to have the chance to be with leading PAT practitioners and exchange and discuss about the current trends, opportunities and challenges in the pharma business. I enjoyed many high-quality talks."
Head of Advanced Analytical Technologies, Roche
"The great opportunity to meet with PAT experts and share the advances and usage of PAT and chemometrics models within my company. Delighted to have learned more on other platforms such as Biotech and Cell and Gene Therapies."
Global Statistical & PAT Lead, Novartis
Our Partners:
